Randomized, Controlled Study of Bleselumab (ASKP1240) Pharmacokinetics and Safety in Patients With Moderate-To-Severe Plaque Psoriasis

Biopharmaceutics and Drug Disposition - United Kingdom
doi 10.1002/bdd.2130
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Population Pharmacokinetics of Brodalumab in Patients With Moderate to Severe Plaque Psoriasis

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2019English

Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study

Journal of the American Academy of Dermatology
Dermatology
2020English

Safety and Efficacy of Guselkumab in Japanese Patients With Moderate-To-Severe Plaque Psoriasis: A Randomised, Placebo-Controlled, Ascending Dose Study

British Journal of Dermatology
DermatologyMedicine
2018English

Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2004English

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study

SKIN The Journal of Cutaneous Medicine
2019English

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

JAMA Dermatology
DermatologyMedicine
2020English

Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2005English

The Experience of Pain and Redness in Patients With Moderate to Severe Plaque Psoriasis

Journal of Dermatological Treatment
Dermatology
2015English

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients With Moderate-To-Severe Plaque Psoriasis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy